Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Quanlu Wan is a traditional Chinese medicine (TCM) pill manufactured by Yaodu Zhangshu Pharmaceutical, a subsidiary of Renhe Group. It is a complex multi-ingredient formulation traditionally used to warm the kidney, strengthen Yang, replenish essence, and nourish blood. The formulation typically includes various deer-derived components (such as deer horn, deer glue, and deer kidney) along with a wide array of medicinal herbs including Ginseng, Astragalus, and Rehmannia. It is primarily indicated for patients suffering from Kidney Yang deficiency, which manifests as general weakness, fatigue, dizziness, tinnitus, lower back and knee pain, and sexual dysfunction such as impotence or spermatorrhea. As a classic TCM formula, it is regulated as an over-the-counter (OTC) pharmaceutical in China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Quanlu Wan.